Grant: Collaborative Health Research Projects
University of Toronto
$128,957.00
Engineering Pulmonary Valve Tissue for Pediatric Patients with Tetralogy of Fallot
FY 2017-18
Summary
Children born with congenital heart diseases, such as tetralogy of Fallot, often have defectiveheart valves. For example, in tetralogy of Fallot, the pulmonary artery and valve are narrowed.Surgeons can enlarge the artery and add a valve leaflet by using a patch made frompericardial tissue from around the heart or a synthetic fabric. While this provides temporaryrelief to the infant or child, the repair materials cannot grow with the patient and are prone toscarring and calcification, leading to a lifetime of reoperations and clinical interventions for thepatient.Here, we propose to use principles of heart valve tissue engineering to produce sheets ofliving valve leaflet tissue that can be used as an alternative repair material. The sheets will bemade from stem cells from the infants own umbilical cord grown on a polyurethane mesh,which will eventually dissolve away in the body to harmless byproducts, leaving behind aliving valve leaflet produced by the stem cells. To kickstart tissue production, we will first growthe valve tissue in bioreactors that exercise the tissue to improve its strength and flexibility.Most engineered valve tissue fails by scarring, so to prevent this, we will inject nanoparticlesloaded with an anti-scarring drug into the tissue prior to implantation. We will test this novelreplacement tissue in pigs to assess whether the material is durable, does not scar, andremains functional in the body.Over the next three years, our interdisciplinary team of material scientists, heart valveexperts, and cardiac surgeons will train next-generation engineers, scientists, and surgeonsand will collaborate with our partners at SickKids Hospital and Tissue RegenerationTherapuetics to translate this novel concept in congenital heart defect repair towards practice,significant improvement in the current standard of care, and economic impact throughcommercialization.
Program
Collaborative Health Research Projects
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
508364-2017
Name nom
Simmons, Craig
Department département
Mechanical and Industrial Engineering
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
128957
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
1
Nb partie
3
Application title
Engineering Pulmonary Valve Tissue for Pediatric Patients with Tetralogy of Fallot
Keyword
NSERC
Application summary
Children born with congenital heart diseases, such as tetralogy of Fallot, often have defectiveheart valves. For example, in tetralogy of Fallot, the pulmonary artery and valve are narrowed.Surgeons can enlarge the artery and add a valve leaflet by using a patch made frompericardial tissue from around the heart or a synthetic fabric. While this provides temporaryrelief to the infant or child, the repair materials cannot grow with the patient and are prone toscarring and calcification, leading to a lifetime of reoperations and clinical interventions for thepatient.Here, we propose to use principles of heart valve tissue engineering to produce sheets ofliving valve leaflet tissue that can be used as an alternative repair material. The sheets will bemade from stem cells from the infants own umbilical cord grown on a polyurethane mesh,which will eventually dissolve away in the body to harmless byproducts, leaving behind aliving valve leaflet produced by the stem cells. To kickstart tissue production, we will first growthe valve tissue in bioreactors that exercise the tissue to improve its strength and flexibility.Most engineered valve tissue fails by scarring, so to prevent this, we will inject nanoparticlesloaded with an anti-scarring drug into the tissue prior to implantation. We will test this novelreplacement tissue in pigs to assess whether the material is durable, does not scar, andremains functional in the body.Over the next three years, our interdisciplinary team of material scientists, heart valveexperts, and cardiac surgeons will train next-generation engineers, scientists, and surgeonsand will collaborate with our partners at SickKids Hospital and Tissue RegenerationTherapuetics to translate this novel concept in congenital heart defect repair towards practice,significant improvement in the current standard of care, and economic impact throughcommercialization.